Bristol Myers Pauses Zola-Cel Program to Review Clinical Data
BMY sits 58% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb has voluntarily paused its Zola-Cel program to review clinical data. The company spokesperson confirmed the pause, but no details were provided on the specific safety or efficacy concerns prompting the review. This is a significant development for a clinical-stage asset, as pauses often signal potential issues that could delay or derail development. The news comes amid a strong run for BMY, with the stock trading near its 52-week high following a strong Q2 and positive pipeline updates. Investors will be watching for further clarity on the nature of the data review and any impact on the program's timeline.
At the time of this announcement, BMY was trading at $67.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $136.5B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.